PD-L1 Antibody Comparison in Urothelial Carcinoma (European Urology)

Following the recent recognition that low PD-L1 expression is associated with inferior survival in urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICIs) in the first-line setting, PD-L1 testing is currently required for selection of patients [1,2]. However, the predictive value of PD-L1 in platinum-pretreated patients is controversial [3-5], and discrepancies may be attributed to different antibody clones, staining platforms, and scoring algorithms for determining PD-L1 status (Table 1).